secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2026-03-25T23:59:59+00:00
Accession:  0001708599-26-000018
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Serina Therapeutics reports FY2025 net loss of $19.4M; SER-252 Phase 1b initiated; up to $30M financing closed
--------------------------------------------------------------------------------

- Net loss $19.4M ($1.91/share) vs $11.1M ($1.51/share) in FY2024; operating expenses rose to $24.2M from $17.1M.
- FDA IND cleared for SER-252 (advanced Parkinson's); first patient dosed in Phase 1b trial in February 2026.
- Private placement of up to $30M closed; $16M received as of March 23, 2026; Greg Bailey appointed Co-Chairman.
- ATM program raised $12.9M from 3.5M shares at avg $3.72; additional $10M raised in 2026.
- Cash and cash equivalents $3.1M as of December 31, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000170859926000018/0001708599-26-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000170859926000018/ser-20260325.htm
  HTML page:      https://secwatch.observer/filing/0001708599-26-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer